

## CLAIMS

1. A crystal of 4,6-dimethyl-4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]nicotinamide.

5

2. The crystal according to claim 1, which has peaks of 2θ (°) at 5.94, 9.94, 15.64, 15.88, 18.48, 20.04 and 20.76 in X-ray powder diffraction.

10 3. The crystal according to claim 1, which has peaks of 2θ (°) at 10.60, 12.90 and 17.24 in X-ray powder diffraction.

4. The crystal according to claim 1, which has a  
15 thermal absorption peak at 195 to 198 °C (onset) in DSC analysis.

5. The crystal according to claim 2, which has a  
thermal absorption peak at 195 to 198 °C (onset) in DSC  
20 analysis.

6. The crystal according to claim 3, which has a  
thermal absorption peak at 195 to 198 °C (onset) in DSC  
analysis.

25

7. A solid pharmaceutical composition comprising the crystal according to claim 1 and a pharmaceutically acceptable carrier.